Impact and modulation of nasal obstruction

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 57, Issue 75, 2002, Pages 25-28

  Horak, Friedrich ^a  

^a Ear Nose and Throat Clinic ^*  (Austria)

Author keywords

Desloratadine; Hay fever (seasonal allergic rhinitis); Histamine H1 antagonists; Nasal obstruction; Rhinomanometry

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE C4; PLACEBO; PROSTAGLANDIN D2;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; NOSE OBSTRUCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOMANOMETRY; SCORING SYSTEM; TREATMENT OUTCOME;

HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; NASAL OBSTRUCTION; RANDOMIZED CONTROLLED TRIALS; RHINITIS, ALLERGIC, SEASONAL;

EID: 0036966513     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108;57(Suppl. 5):S147-S334.
2. ANDERSSON KE, BENDE M. Adrenoreceptors in the control of human nasal mucosa blood flow. Ann Otol Rhinol Laryngol 1984;93:179-182.
3. FERGUSON BJ, PARAMAESVARAN S, RUBINSTEIN E. A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa. Otolaryngol Head Neck Surg 2001;125:253-260.
4. BACHERT C, GEVEART P. Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators. Allergy 1999;54;(Suppl. 57):116-123.
5. BACHERT C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002;57(Suppl. 75):13-18.
6. GEHA RS, MELTZER EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-762.
7. MELTZER EO, PRENNER BM, NAYAK A et al. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy season. Clin Drug Invest 2001;21:25-32.
8. BACHERT C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(Suppl. 65):14-20.
9. HORAK F, STÜBNER P, ZIEGLMAYER R, HARRIS AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109:956-961.
10. CANONICA GW. Introduction to the nasal and pulmonary allergy cascade. Allergy 2002;57(Suppl. 75):8-12.
11. BISGAARD H, OLSSON P, BENDE M. Effect of leukotriene D4 on nasal mucosa blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-297.
12. WANG DY, CLEMENT P, SMITZ J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol 1996;116:91-96.
13. MOLET S, GOSSET P, LASSALLE P, CZARLEWSKI W, TONNEL AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997;27:1167-1174.
14. SCHROEDER JT, SCHLEIMER RP, LICHTENSTEIN LM, KREUTNER W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001;31:1369-1377.
15. DONOVAN JP, BUCKERIDGE DL, BRISCOE MP, CLARK RH, DAY JH. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 1996;77:74-80.
16. HORAK F, STÜBNER P, ZIEGLMAYER R, MOSER M, KAWINA A, ENGELBRECHT W. Decongestant activity of desloratadine in controlled-allergen-exposure trials. Clin Drug Invest 2002;22(Suppl. 2):13-20.